(1 - 7 von 8
)
atugen unterzeichnet Forschungsabkommen mit Roche
www.ots.at
— ... unserer Target Validation Technologie," sagte Dr. Zisi Fotev, Vice President Business Development der atugen Aktiengesellschaft. › amp › OTS_ _OTS0072
GeneBloc technology – Innovations Report
www.innovations-report.de
... regulated by an important cellular enzyme phosphatidyl-inositol 3-kinase" says Klaus Giese. Zisi Fotev | atugen AG Weitere Informationen:
Germany or Bust: US Biotechs Head East | IATP
www.iatp.org
Wall Street Journal | By Christopher Cooper, Staff Reporter of The Wall Street Journal
atugen Announces Functional Genomics Collaboration with Byk
www.globenewswire.com
Dr. Zisi Fotev, VP of Business Development of atugen commented, "This deal further exemplifies atugen as a global leader in genetic target validation.
atugen Accelerates Successful Drug Discovery Programme at
www.globenewswire.com
— ... pleased to be able to fulfill the terms of the agreement in record time," Dr Zisi Fotev, VP of Business Development of atugen commented their novel targets, with the aim of cutting the cost and time taken to develop new drugs," said Dr Zisi Fotev, VP of Business Development of atugen. › ...
与Byk Gulden（链接）的Atugen AG标志评估协议
www.csretailpro.com
— atugen AG, Berlin Dr. Zisi Fotev Tel: + Fax: + NoonanRusso Ltd. Dr. Don O'Sullivan Tel : + Fax ... › atug...
sortiert nach Relevanz / Datum